TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer

Shun Lu, Mariano Provencio Pulla, Eldsamira Mascarenhas, Junko Tanizaki, Hye Ryun Kim, Yinglei Liu, Shengmei Feng, Biao Zhang, Laurence Toms, James Chih-Hsin Yang, Sarah B. Goldberg

Therapeutic Advances in Medical Oncology

Published online on May 20, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Osimertinib is a first-line (1L) treatment option for patients with locally advanced/metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Resistance to 1L osimertinib often develops and treatment ...